Andrew Tutt - Publications, H-index & Citations

Andrew Tutt

The Institute of Cancer Research

103H指数

779论文数

8.7W被引数

收录论文 184

发表时间

PUM3 is an essential suppressor of replication stress in homologous recombination deficient breast cancer PUM3是同源重组缺陷型乳腺癌中复制应激所必需的抑制因子

Nature Communications

IF15.7

2026-09-21

OAAI

Valeria Amodeo; Daniel Weekes; Nicolae Balan; Rebeca Uceda Castro; Nadja D’Uonno; Asha Konde; Elodie Noel; Luisa Robbez-Masson; Jennifer Trendell; Maya Shlomi; Callum Walker; Anjan Venkatesh; Colm J. Ryan; Sarah C. Moser; Jos Jonkers; Laurence H. Pearl; Antony W. Oliver; Dragomir B. Krastev; Syed Haider; Anita Grigoriadis; Stephen J. Pettitt; Christopher J. Lord; Andrew N. J. Tutt

The anion channel GPR89 is a tumor-specific dependency in breast cancer GPR89阴离子通道是乳腺癌的肿瘤特异性依赖

Nature Communications

IF15.7

2026-08-24

OAAI

Riccardo Ferro; Alexandra Carroll; Ana M. Mendes-Pereira; Virinder Reen; George Vlachogiannis; Rebeca Uceda-Castro; Dragomir Krastev; Valeria Amodeo; Stephen Pettitt; Nadja D’Uonno; Ioanna Mavrommati; Blanca Navarro; Luke Hitchen; Jennifer Trendell; Ana Stojiljkovic; Cynthia Prince; Narinder Janghra; Ioannis Roxanis; Patrycja Gazinska; Daniel Larcombe-Young; Rebecca Marlow; Stefano Annunziato; Jos Jonkers; Tejashree Rajaram Kanitkar; Amadeus Xu; Nirmesh Patel; Nalan Liv; John Alexander; Jelmar Quist; Mercedes Pardo; Theodoros I. Roumeliotis; Jyoti S. Choudhary; Daniel Weekes; Pierfrancesco Marra; Joanna I. Loizou; Rachael Natrajan; Anita Grigoriadis; Mallur Srivatsan Madhusudhan; Syed Haider; Christopher J. Lord; Andrew Tutt

Two decades of PARP inhibitor synthetic lethality in cancer 二十年来PARP抑制剂在癌症中的合成致死率

Nature

IF48.5

2026-05-06

PREAI

Christopher J. Lord; Andrew N. J. Tutt; Alan Ashworth

NASP modulates histone turnover to drive PARP inhibitor resistance NASP通过调节组蛋白周转来驱动PARP抑制剂耐药性。

Nature

IF48.5

2025-08-13

PREAI

Sarah C. Moser; Anna Khalizieva; Josef Roehsner; Elisabeth Pottendorfer; Milo L. Kaptein; Giulia Ricci; Vivek Bhardwaj; Onno B. Bleijerveld; Liesbeth Hoekman; Ingrid van der Heijden; Simone di Sanzo; Alexander Fish; Aleksandra Chikunova; Judith H. I. Haarhuis; Roel Oldenkamp; Luisa Robbez-Masson; Justin Sprengers; Daniel J. Vis; Lodewyk F. A. Wessels; Marieke van de Ven; Stephen J. Pettitt; Andrew N. J. Tutt; Christopher J. Lord; Benjamin D. Rowland; Moritz Völker-Albert; Francesca Mattiroli; Thijn R. Brummelkamp; Abdelghani Mazouzi; Jos Jonkers

The untapped potential of radiation and immunotherapy for hormone receptor-positive breast cancer 激素受体阳性乳腺癌中放射治疗和免疫治疗的未开发潜力

npj Breast Cancer

IF7.6

2025-07-24

OAAI

Matthew Fenton; Miki Yoneyama; Erik Wennerberg; Tom Lund; Andrew Tutt; Alan Melcher; Sandra Demaria; Navita Somaiah

Proteogenomic discovery of RB1-defective phenocopy in cancer predicts disease outcome, response to treatment, and therapeutic targets 蛋白质组学发现RB1缺陷表型复制可预测癌症的疾病结局、治疗反应和 therapeutic targets。

SCIENCE ADVANCES

IF12.5

2025-03-28

PREAI

Iacovacci, Jacopo; Brough, Rachel; Moughari, Fatemeh Ahmadi; Alexander, John; Kemp, Harriet; Tutt, Andrew N. J.; Haider, Syed

Unraveling complexity and leveraging opportunities in uncommon breast cancer subtypes

NPJ BREAST CANCER

IF7.6

2025-01-24

OAAI

Pareja, Fresia; Bhargava, Rohit; Borges, Virginia F.; Brogi, Edi; Canas Marques, Rita; Cardoso, Fatima; Desmedt, Christine; Harigopal, Malini; Lakhani, Sunil R.; Lee, Adrian; Leone, Jose Pablo; Linden, Hannah; Lord, Christopher J.; Marchio, Caterina; Merajver, Sofia D.; Rakha, Emad; Reis-Filho, Jorge S.; Richardson, Andrea; Sawyer, Elinor; Schedin, Pepper; Schwartz, Christopher J.; Tutt, Andrew; Ueno, Naoto T.; Vincent-Salomon, Anne; Weigelt, Britta; Wen, Y. Hannah; Schnitt, Stuart J.; Oesterreich, Steffi

Persistence of BRCA1 and RAD51C methylation after neoadjuvant chemotherapy in high risk TNBC

EUROPEAN JOURNAL OF CANCER

IF7.1

2024-10-01

PREAI

Pettitt, S.; Proszek, P.; Torga, G.; Gulati, A.; Llop-Guevara, A.; Jank, P.; Felder, B.; Rodriguez, A.; Cooke, S.; Garcia-Murillas, I.; Ravindran, N.; Alaguthurai, T.; Jones, L.; Roxanis, Y.; Serra, V.; Denkert, C.; Loibl, S.; Haider, S.; Lord, C.; Tutt, A.

Targeting GPR89 as a novel therapeutic strategy for breast cancer

EUROPEAN JOURNAL OF CANCER

IF7.1

2024-10-01

PREAI

Ferro, R.; Carroll, A.; Hickman, O.; Vlachogiannis, G.; Trendell, J.; Krastev, D.; Pettitt, S.; Amodeo, V.; Annunziato, S.; Jonkers, J.; Liv, N.; Pardo, M.; Roumeliotis, T. I.; Choudhary, J.; Natrajan, R.; Grigoriadis, A.; Madhusudhan, M. S.; Haider, S.; Lord, C. J.; Tutt, A.

PAK6 acts downstream of IQGAP3 to promote contractility in triple negative breast cancer cells

CELLULAR SIGNALLING

IF3.7

2024-09-01

OAAI

Pipili, Aikaterini; Babteen, Nouf A.; Kuwair, Lujain; Jannet, Mahfuja Bulu; Quist, Jelmar; Ong, Karine K. V.; Pitaluga, Ryan; Grigoriadis, Anita G.; Tutt, Andrew; Wells, Claire M.

Anti-EGFR Antibody-Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth

CLINICAL CANCER RESEARCH

IF10.2

2024-05-21

OAAI

Cheung, Anthony; Chenoweth, Alicia M.; Johansson, Annelie; Laddach, Roman; Guppy, Naomi; Trendell, Jennifer; Esapa, Benjamina; Mavousian, Antranik; Navarro-Llinas, Blanca; Haider, Syed; Romero-Clavijo, Pablo; Hoffmann, Ricarda M.; Andriollo, Paolo; Rahman, Khondaker M.; Jackson, Paul; Tsoka, Sophia; Irshad, Sheeba; Roxanis, Ioannis; Grigoriadis, Anita; Thurston, David E.; Lord, Christopher J.; Tutt, Andrew N. J.; Karagiannis, Sophia N.

Functional assessment of RAD51 foci and replication fork dynamics in PARPi resistant BRCA1/2 mutated breast cancer

CANCER RESEARCH

IF16.6

2024-05-02

PREAI

Harvey-Jones, Elizabeth; Raghunandan, Maya; Robbez-Masson, Luisa; Alaguthurai, Thanussuyah; Llop-Guevara, Alba; Trendell, Jennifer; Rodriguez, Olga; Guzman, Marta; Weekes, Daniel; deRenty, Christelle; Knight, Eleanor; Marlow, Rebecca; Starling, Christopher; Liu, Ruifang; Ravindran, Nivedita; Roxanis, Ioannis; Lukashchuk, Natalia; Serra, Violeta; Pettitt, Stephen; Lord, Christopher; Tutt, Andrew N. J.

Longitudinal pro fi ling identi fi es co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer

ANNALS OF ONCOLOGY

IF65.4

2024-04-01

OAAI

Harvey-Jones, E.; Raghunandan, M.; Robbez-Masson, L.; Magraner-Pardo, L.; Alaguthurai, T.; Yablonovitch, A.; Yen, J.; Xiao, H.; Brough, R.; Frankum, J.; Song, F.; Yeung, J.; Savy, T.; Gulati, A.; Alexander, J.; Kemp, H.; Starling, C.; Konde, A.; Marlow, R.; Cheang, M.; Proszek, P.; Hubank, M.; Cai, M.; Trendell, J.; Lu, R.; Liccardo, R.; Ravindran, N.; Llop-Guevara, A.; Rodriguez, O.; Balmana, J.; Lukashchuk, N.; Dorschner, M.; Drusbosky, L.; Roxanis, I.; Serra, V.; Haider, S.; Pettitt, S. J.; Lord, C. J.; Tutt, A. N. J.

Cancer-associated FBXW7 loss is synthetic lethal with pharmacological targeting of CDC7 癌症相关的FBXW7丢失是合成致死的，具有CDC7的药理学靶向作用

MOLECULAR ONCOLOGY

IF4.5

2023-10-22

OAAI

Baxter, Joseph S.; Brough, Rachel; Krastev, Dragomir B.; Song, Feifei; Sridhar, Sandhya; Gulati, Aditi; Alexander, John; Roumeliotis, Theodoros I.; Kozik, Zuza; Choudhary, Jyoti S.; Haider, Syed; Pettitt, Stephen J.; Tutt, Andrew N. J.; Lord, Christopher J.

Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

CLINICAL CANCER RESEARCH

IF10.2

2023-08-14

OAAI

Tovey, Holly; Sipos, Orsolya; Parker, Joel S.; Hoadley, Katherine A.; Quist, Jelmar; Kernaghan, Sarah; Kilburn, Lucy; Salgado, Roberto; Loi, Sherene; Kennedy, Richard D.; Roxanis, Ioannis; Gazinska, Patrycja; Pinder, Sarah E.; Bliss, Judith; Perou, Charles M.; Haider, Syed; Grigoriadis, Anita; Tutt, Andrew; Cheang, Maggie Chon U.

A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-increment 11q splice variant

ONCOGENE

IF7.3

2023-07-25

OAAI

Pettitt, Stephen J.; Shao, Nan; Zatreanu, Diana; Frankum, Jessica; Bajrami, Ilirjana; Brough, Rachel; Krastev, Dragomir B.; Roumeliotis, Theodoros I.; Choudhary, Jyoti S.; Lorenz, Sonja; Rust, Alistair; de Bono, Johann S.; Yap, Timothy A.; Tutt, Andrew N. J.; Lord, Christopher J.

Serum-derived extracellular vesicles from breast cancer patients contribute to differential regulation of T-cell-mediated immune-escape mechanisms in breast cancer subtypes 乳腺癌患者血清来源的细胞外囊泡有助于乳腺癌亚型中T细胞介导的免疫逃逸机制的差异调节

FRONTIERS IN IMMUNOLOGY

IF5.9

2023-06-22

OAAI

Graham, Rosalind; Gazinska, Patrycja; Zhang, Birong; Khiabany, Atousa; Sinha, Shubhankar; Alaguthurai, Thanussuyah; Flores-Borja, Fabian; Vicencio, Jose; Beuron, Fabienne; Roxanis, Ioannis; Matkowski, Rafal; Liam-Or, Revadee; Tutt, Andrew; Ng, Tony; Al-Jamal, Khuloud T.; Zhou, You; Irshad, Sheeba

Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial (Apr, 10.1007/s12282-023-01451-8, 2023)

BREAST CANCER

IF2.9

2023-05-12

OAAI

Yamauchi, Hideko; Toi, Masakazu; Takayama, Shin; Nakamura, Seigo; Takano, Toshimi; Cui, Karen; Campbell, Christine; De Vos, Liesbet; Geyer, Charles; Tutt, Andrew

MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells MND1和PSMC3IP控制有丝分裂细胞的PARP抑制剂敏感性

CELL REPORTS

IF6.9

2023-05-01

OAAI

Zelceski, Anabel; Francica, Paola; Lingg, Lea; Mutlu, Merve; Stok, Colin; Liptay, Martin; Alexander, John; Baxter, Joseph S.; Brough, Rachel; Gulati, Aditi; Haider, Syed; Raghunandan, Maya; Song, Feifei; Sridhar, Sandhya; Forment, Josep, V; O'Connor, Mark J.; Davies, Barry R.; van Vugt, Marcel A. T. M.; Krastev, Dragomir B.; Pettitt, Stephen J.; Tutt, Andrew N. J.; Rottenberg, Sven; Lord, Christopher J.

BRCA1 promoter methylation in sporadic breast cancer patients detected by liquid biopsy

CANCER RESEARCH

IF16.6

2023-04-04

PREAI

Yen, Jennifer; Chen, Sai; Jenkins, Colby; Overstreet, Brooke; Fu, Yu; Zhao, Jun; Jiang, Tingting; Drusbosky, Leylah; Pettitt, Stephen; Dorschner, Michael; Lawrence, Lauren; Chuang, Han-Yu; Tutt, Andrew

研究方向